Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, several companies reported positive results from trials including Initiator Pharma, Curasight and Fluoguide. Fluoguide only rose by 4% while Curasight fell by 1%. Their week performance following the announcements can be explained by the companies’ already strong year-to-date performance.
7 of the 20 listed, Danish biotech companies have published news the past week. 11 of the 20 companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Saniona is now the best performing stock this year.
Company news the past week
Ascendis Pharma
Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany (Link)
Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (Link)
No news the past week
Cessatech
No news the past week
No news the past week
Curasight A/S reports positive preclinical results with uTREAT[®] in aggressive brain cancer (glioblastoma) (Link)
Evaxion Biotech
No news the past week
Expres2ion
No news the past week
Fluoguide
FluoGuide announces positive topline results from phase IIa trial of FG001 in lung cancer (Link)
Genmab
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023 (Link)
Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference (Link)
Gubra
Gubra announces updates to its pipeline. Internally developed brain-accessible orexin peptides for the treatment of narcolepsy, now ready for partnering (Link)
Initiator Pharma
Initiator Pharma reports dose-dependent significant efficacy of IP2018 in the placebo-controlled Phase IIa clinical trial of Erectile Dysfunction (Link)
IO Biotech
No news the past week
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
No news the past week
SynAct Pharma
No news the past week
ViroGates
No news the past week
Zealand Pharma
Zealand Pharma to Participate in Upcoming Healthcare Conferences (Link)
Y-mAbs Therapeutics
No news the past week
2cureX
No news the past week
SELECTED CASES
SHARE PRICE DEVELOPMENTS
The majority of the Danish Biotech stocks delivered a negative share price performance last week. The average return was however positive with 2.4%. Initiator Pharma rose 35% after they reported positive phase IIb studies with IP2018 against erectile dysfunction. Fluoguide rose just 4% after positive phase 2 results from its lead candidate FG001, which can make cancer cells luminescent. However, the explanation may be that the stock is already up 134% year-to-date. Curasight A/S, Fluoguide A/S and Saniona AB have been the best performing stocks year-to-date after soaring 134-154% after among other things partnerships and positive recommendations paving the way for approvals.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months
